Editorial explainer
Is tirzepatide a peptide or a GLP-1?
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last reviewed: 2026-06-11
Independent, and paid nothing. We take no commission, no referral fee and no payment from any retailer, clinic or pharmacy on this site. Outbound links are ordinary untracked links. How we are funded.
Tirzepatide is both. It is a synthetic peptide, a chain of amino acids, and it works as a dual agonist on the GIP and GLP-1 receptors. So calling it simply "a GLP-1" is a useful shorthand but not strictly accurate: GLP-1-only medicines such as semaglutide act on one receptor, while tirzepatide acts on two. In the UK it is sold under the brand name Mounjaro and is a prescription-only medicine. PeptideClear is editorial commentary, not clinical advice; whether tirzepatide is appropriate for anyone is a decision for a UK-licensed prescriber.
Peptide, GLP-1, GIP: getting the words straight
The confusion comes from mixing two different kinds of label. "Peptide" describes what the molecule is: a short chain of amino acids. "GLP-1 receptor agonist" describes what part of the molecule does: it activates the GLP-1 receptor. Those are not competing answers. Tirzepatide is a peptide whose action includes the GLP-1 receptor, and also the GIP receptor.
That dual action is the headline difference from the GLP-1-only peptides. Semaglutide, the active ingredient in Ozempic and Wegovy, is a peptide that acts on the single GLP-1 receptor. Tirzepatide adds GIP receptor activity on top. Both sit in the same broad family of peptide-based metabolic medicines, and both are prescription-only.
None of that is a recommendation. Which medicine, if any, suits a given person is a clinical decision. The purpose here is only to clear up the category, because the labels are used loosely everywhere else.